摘要:
Calcium fluoride with high purity of very small content of unreacted calcium carbonate and silica is recovered from an etchant mainly composed of hydrogen fluoride or hydrogen fluoride and ammonium fluoride. The etchant is reacted with calcium carbonate with transfer directions of the etchant and calcium carbonate being controlled within a composition region in which mole equivalent ratio of ammonium fluoride/hydrogen fluoride is specified.
摘要:
Fluorine is recovered as calcium fluoride from a fluoroetchant solution composed mainly of hydrogen fluoride and ammonium fluoride using a sealed reaction tank equipped with a supply port for adding the fluoroetchant solution to the tank, a supply port for adding calcium carbonate to the tank, a vapor supply port for adding steam to heat the solution in the tank, an air supply port for providing air to aerate the contents of the tank, a stirrer for stirring the contents of the tank, an ejector for removing vapors from the tank connected to the tank via a mist separator for separating mist from the vapors being removed from the tank, and an exhaust port for removing calcium fluoride from the tank.
摘要:
A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R3 is a halogen atom. However, R1 is a halogen atom when X is CR3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.
摘要:
The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.
摘要:
A three-dimensional display comprising a flat light source, a vertical striped filter having slits transmitting light from the light source and barriers screening the light from the light source alternately formed therein for partially transmitting the light from the light source, and an LCD panel arranged on the light emission side of the vertical striped filter and having left eye pixels and right eye pixels alternately formed therein, light passing through the left eye pixels in the LCD panel and light passing through the right eye pixels being emitted toward a observer in a separated state.
摘要:
In a simultaneous communication as in a POS system in which the same data including a multiplicity of data blocks is transmitted from a controller to a multiplicity of terminals all at once, the controller transmits all of the data blocks to the terminals without receiving any acknowledgement from each of the terminals in the course of data transmission. Each time the data block is received, the terminals hold information concerning the acknowledgement of the data block. After the termination of transmission of the whole of the data, the controller receives the acknowledgement information from each terminal into a management table. Based on the contents of the mangement table, the controller retransmits the data to a terminal(s) indicative of a negative acknowledgement in a similar manner to the above-mentioned data transmission or while taking acknowledgement for each data block.
摘要:
The present invention is directed to a three-dimensional display panel capable of viewing a three-dimensional image without using special glasses. The three-dimensional display panel comprises an image display panel having a column of right eye pixels arranged with predetermined spacing in the longitudinal direction on a screen and a column of left eye pixels arranged with predetermined spacing in the longitudinal direction on the screen and so adapted that the column of right eye pixels and the column of left eye pixels are arranged alternately in close proximity to each other in the horizontal direction on the screen and are shifted from each other in the longitudinal direction on the screen to ensure a region where means for switching the respective pixels is formed, and image separating means for separating light from the right eye pixels and light from the left eye pixels to be respectively incident on the right eye and the left eye of a viewer.
摘要:
A flat display includes a closed vessel having a front panel (optically transparent) and a back panel, apparatus for emitting electrons by field emission positioned on the back panel, an anode having an anode electrode and at least a phosphor layer positioned on the front panel, and a spacer for defining a distance between the front panel and the back panel. The spacer has an upper cross-section adjacent to the front panel and a lower cross-section adjacent to the back panel. The lower cross-section is larger than the upper cross-section.
摘要:
To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt:
摘要:
To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt: